blog.aids.gov — HIV Policy & Programs. Research. New Media.
HIV Policy & Programs. Research. New Media.
Earlier this week the Food and Drug Administration (FDA) announced the approval of the INSTI™ HIV-1 Antibody Test, a new, single use rapid test for the detection of HIV antibodies developed by bioLytical Laboratories of Canada. The newly approved test provides results in as little as 60 seconds, in contrast to the six previously approved…
Every year on December 1, we commemorate World AIDS Day to bring attention to the tremendous impact of the HIV epidemic in the United States and around the world. In observance of World AIDS Day, today CDC launched a special report, CDC Vital Signs on HIV Testing in the United States, in recognition of the…
Today, the New England Journal of Medicine published research findings from the iPrEx study funded by the National Institutes of Health (NIH) and the Bill and Melinda Gates Foundation testing the efficacy of pre-exposure prophylaxis (PrEP). The study is a major step forward in our ability to prevent new HIV infections. The study found that…
WASHINGTON, D.C. – Today, the National Institutes of Health announced findings on recent HIV prevention research. The study finds that a daily dose of an oral antiretroviral drug taken by HIV-negative gay and bisexual men reduced the risk of acquiring HIV infection by 43.8 percent, and had even higher rates of effectiveness, up to 73…
The National Institutes of Health National Institute of Allergy and Infectious Diseases just made a significant announcement on pre-exposure prophylaxis (PrEP). I am proud to share this important update from the NIH with our blog readers. Learn more by reading this Q&A.
On Tuesday, October 26, more than 300 representatives from our current HIV clinical trial networks, the infectious diseases research community, and HIV advocacy groups attended the “Town Hall Meeting to Examine the Restructuring of the NIAID Clinical Trials Networks.” The goals of the meeting were to: Provide NIAID’s overarching vision for the future of its…
Co-authored by Hugh Auchincloss, M.D., NIAID Deputy Director and Carole Heilman, Ph.D., Director of NIAID’s Division of Microbiology and Infectious Diseases So far all of the postings on this blog series have been about HIV/AIDS research or about diseases that are major comorbidities. This is appropriate since we have been discussing the upcoming re-competition of…
Co-authored by Edward Handelsman, M.D., Chief of NIAID’s Pediatric Medicine Branch within the Division of AIDS, and Lynne Mofenson, M.D., Chief of the Pediatric, Adolescent and Maternal AIDS Branch within the Eunice Kennedy Shriver National Institute of Child Health & Human Development. As a result of our continued dialogue with our collaborators and stakeholders, NIAID…
